J. Ferlay, E. Steliarova-foucher, and J. Lortet-tieulent, Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012, European Journal of Cancer, vol.49, issue.6, pp.1374-403, 2013.
DOI : 10.1016/j.ejca.2012.12.027

B. Kjeldsen, O. Kronborg, and C. Fenger, The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests, International Journal of Colorectal Disease, vol.12, issue.6, pp.329-363, 1997.
DOI : 10.1007/s003840050118

C. Bokemeyer, I. Bondarenko, and J. Hartmann, Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study, Annals of Oncology, vol.69, issue.7, pp.1535-1581, 2011.
DOI : 10.1158/0008-5472.CAN-08-2466

E. Van-cutsem, C. Kohne, and E. Hitre, Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer, New England Journal of Medicine, vol.360, issue.14, pp.1408-1425, 2009.
DOI : 10.1056/NEJMoa0805019

J. Douillard, K. Oliner, and S. Siena, Mutations in Colorectal Cancer, New England Journal of Medicine, vol.369, issue.11, pp.1023-1057, 2013.
DOI : 10.1056/NEJMoa1305275

URL : https://hal.archives-ouvertes.fr/hal-02109307

A. Lievre, P. Artru, and M. Guiu, The KRAS mutation detection within the initial management of patients with metastatic colorectal cancer: A status report in France in 2011, European Journal of Cancer, vol.49, issue.9, pp.2126-2159, 2013.
DOI : 10.1016/j.ejca.2013.02.016

URL : https://hal.archives-ouvertes.fr/hal-00974915

, Summary of Product Characteristics. Erbitux® (cetuximab), last updated 27, 2014.

, Summary of Product Characteristics Vectibix® (panitumumab), last updated 26, 2015.

F. Bibeau, C. Louvet, and P. Afchain, Observational study on conditions for access to the